Crossmark

Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review

Crossref DOI link: https://doi.org/10.1007/s11657-018-0443-7

Published Online: 2018-03-22

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fujiwara, Saeko

Miyauchi, Akimitsu

Hamaya, Etsuro

Nicholls, Rebecca Jayne

Weston, Adele

Baidya, Santwona

Pinto, Lionel

Barron, Rich

Takada, Junichi
License Information

Text and Data Mining valid from 2018-03-22
More Information

Article History

Received: 29 August 2017

Accepted: 6 March 2018

First Online: 22 March 2018

Change Date: 8 May 2018

Change Type: Correction

Change Details: In this article it was mistakenly stated that Akimitsu Miyauchi is affiliated with both Miyauchi Medical Center, Osaka and Amgen Astellas BioPharma K.K., Tokyo. In fact he is affiliated only with Miyauchi Medical Center; he has no connection with Amgen Astellas.

Compliance with ethical standards

:

: Drs. Miyauchi and Fujiwara received consulting fees from Amgen Astellas BioPharma K.K. and Dr. Fujiwara is on the Speakers Bureau of Asahi-Kasei Pharma, Alere Medical and Pfizer. Ms. Nicholls is a full-time employee of MAPI Real World Evidence. Mr. Hamaya is a full-time employee of Amgen Astellas Biopharma K.K. and owns stock in Amgen, Inc. and Eli Lilly. Drs. Weston and Baidya are full-time employees of Optum. Mr. Barron and Mr. Pinto are full-time employees of and shareholders in Amgen Inc. Dr. Takada has no disclosures related to this manuscript.